Clinical Research Directory
Browse clinical research sites, groups, and studies.
Normal-weight Diabetes: Adipocyte-directed Therapy with Pioglitazone or Tirzepatide
Sponsor: Stanford University
Summary
This study is to investigate how adipocyte (fat cell) function and fat distribution differ between individuals with normal-weight type 2 diabetes (NWD) and normal-weight controls without diabetes (NWC). The study will assess whether adipocyte-directed therapies, specifically pioglitazone and tirzepatide, can improve insulin resistance, adipocyte function, and fat distribution in individuals with NWD. By analyzing the biological mechanisms underlying adipocyte dysfunction, the study aims to provide insights into novel treatment strategies for improving metabolic health in normal-weight individuals with type 2 diabetes.
Key Details
Gender
All
Age Range
30 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
104
Start Date
2024-12-15
Completion Date
2027-12-15
Last Updated
2024-10-24
Healthy Volunteers
Yes
Conditions
Interventions
Insulin resistance testing
Steady state Plasma Glucose test
OGTT
Will collect 5 blood draws during the test to measure insulin secretion
Fat biopsy
Needle biopsy to gather a sample of abdominal subcutaneous fat
DXA scan
Whole body DXA scan
MRI
Abdominal MRI
1H-MRS
Spectroscopy of the abdominal region
Tirzepatide
16 weeks started at 2.5mg/week and increased to 5mg/week dose
Pioglitazone
16 weeks at a 45mg/day dose
Locations (1)
Stanford University, Clinical and Translational Research Unit (CTRU)
Stanford, California, United States